Systemic gemcitabine and capecitabine plus intra-arterial epirubicin and cisplatin as second-line chemotherapy in gemcitabine-failure pancreatic cancer

Pancreas

Volumn 40, Issue 6, 2011, Pages 983-984

  Mambrini, Andrea ^a   Bassi, Claudio ^b   Torri, Tito ^a   Orlandi, Massimo ^a   Fiorentini, Giammaria ^c   Cantore, Maurizio ^a  

^a Carrara City Hospital   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c SAN GIUSEPPE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; GEMCITABINE;

ANEMIA; BLOOD TOXICITY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HAND FOOT SYNDROME; HUMAN; LETTER; LIVER METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; ORAL MUCOSAL DISEASE; OVERALL SURVIVAL; PANCREAS CANCER; PERIPHERAL SENSORY NEUROTOXICITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 80051546585     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3182164002     Document Type: Letter

References (10)

1. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 1997;15:2403-2413. (Pubitemid 27251144)
2. Boeck S, Weigang-Kohler K, Fuchs M, et al. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: A multicenter phase II trial. Ann Oncol. 2007;18:745-751. (Pubitemid 46523280)
3. Reni M, Pasetto L, Aprile G, et al. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer. 2006;94:785-791.
4. Barletta E, Fiore F, Daniele B, et al. Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma. Front Biosci. 2006;11:782-787. (Pubitemid 43258181)
5. Demols A, Peeters M, Polus M, et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: A phase II study. Br J Cancer. 2006;94:481-485. (Pubitemid 43289750)
6. Cantore M, Rabbi C, Fiorentini G, et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology. 2004;67:93-97. (Pubitemid 39482675)
7. Kulke MH, Blaszkowsky LS, Ryan DP, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2007;25:4787Y4792.
8. Cantore M, Fiorentini G, Luppi G, et al. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: A prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother. 2004;16:589-594.
9. Reni M, Cordio S, Milandri C, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: A randomised controlled multicentre phase III trial. Lancet Oncol. 2005;6:369-376. (Pubitemid 40753742)
10. Mambrini A, Pacetti P, Del Freo A, et al. Gemcitabine-capecitabine plus intra-arterial epirubicin-cisplatin in pretreated pancreatic cancer patients: A phase I study. Anticancer Res. 2009;29:1547Y1549.